Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(2)
Other(2)

Detailed Status

Terminated2
unknown2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

completed120%
terminated240%
unknown240%

Recent Activity

0 active trials
Showing 5 of 5
unknownphase_2

Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

NCT04992858
unknownphase_1

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

NCT03758287
terminatedphase_1

A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC

NCT03876925
terminatedphase_1

A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

NCT03125876
completedphase_1

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

NCT04577703

Clinical Trials (5)

Showing 5 of 5 trials
NCT04992858Phase 2

Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Unknown
NCT03758287Phase 1

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Unknown
NCT03876925Phase 1

A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC

Terminated
NCT03125876Phase 1

A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

Terminated
NCT04577703Phase 1

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5